Completed OBSERVATIONAL NCT05865262

Protocol TRANS and QT Repolarization (QTrans)

Analysis of Ventricular Repolarization by QT Measurement in Transgender People Treated With Hormone Therapy

Sponsor: APHP

Conditions QTc Interval Transgender Individuals

Interventions ECG blood test (assessing ionic and hormonal circulating levels)

Updated 6 times since 2023 Last updated: Apr 10, 2024 Started: Nov 16, 2021 Primary completion: Nov 16, 2021 Completion: Jan 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on QTc Interval and Transgender Individuals, this trial is completed. The trial is conducted by APHP and has accumulated 6 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
May 2024 — Jul 2024 [monthly]

Completed
Apr 2024 — May 2024 [monthly]

Completed
Jul 2023 — Apr 2024 [monthly]

Completed

▶ Show 1 earlier version

Jun 2023 — Jul 2023 [monthly]

Completed

First recorded

Nov 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

APHP
University Hospital, Bordeaux

Data source: University Hospital, Bordeaux

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pessac, France